Pharmaceutical companies’ traditional focus on discovering the next US$1 billion “blockbuster” drug has shifted in recent years, from products for common diseases to treatments for rare conditions. And in new research we’ve published, we found that legislation enacted to incentivise the pharma industry to invest in medication for rare conditions is now so profitable that ...
How pharmaceutical companies profit from drugs for rare diseases
By Dyfrig Hughes and Jannine Poletti-Hughes
25 Oct 2016